Grace Therapeutics, Inc.
GRCENASDAQHealthcare● Active
$2.31
+$0.01(+0.43%)
Market Cap$35744940
P/E Ratio—
52W High$5.18
52W Low$1.79
Grace Therapeutics, Inc. (GRCE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GRCE · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | — | 61.22% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.02B | $0.02B | $0.07B | $0.02B | $0.03B |
| Operating Income | ($0.02B) | ($0.02B) | ($0.07B) | ($0.02B) | ($0.03B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.02B) | ($0.07B) | ($0.01B) | ($0.03B) |
| Income Tax Expense | ($0.00B) | ($0.00B) | ($0.01B) | ($0.00B) | $0.00B |
| Net Income | ($0.01B) | ($0.02B) | ($0.06B) | ($0.01B) | ($0.03B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.13 | $-1.83 | $-7.72 | $-2.02 | $-12.59 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B |
| EBITDA | ($0.02B) | ($0.02B) | ($0.02B) | ($0.02B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Grace Therapeutics, Inc. data
About Grace Therapeutics, Inc. (GRCE) Income Statement
Grace Therapeutics, Inc. (GRCE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GRCE reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
GRCE · 4 questionsGrace Therapeutics, Inc. (GRCE) reported revenue of $0.00B for 2025, down —% year-over-year.
GRCE revenueGRCE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09